Chargement
x
Ce site Web utilise des cookies essentiels. Avec votre consentement, nous plaçons des cookies Google Analytics à des fins statistiques.

Politique de cookies pour Slzii.com

Ceci est la politique en matière de cookies pour Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

Recherche (Nouvelles)

BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution. SUZHOU, China, Feb. 9, 2026 /PRNewswire/ -- BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ("Kanghong Pharmaceutical"), recognizing BioDlink's critical contribution to the successful clinical approval of KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. KH815 is a first-in-class dual-payload ADC independently developed by Kanghong Pharmaceutical. The program achieved a major regulatory milestone with approval from Australia's Human Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025. As Kanghong Pharmaceutical's CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation, and formulation research. Efficient Execution of a Complex First-in-Class Program KH815 required advanced process design and analytical control, including precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization. Leveraging its expertise in complex ADC development, BioDlink delivered a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines. Despite the complexity of conjugation process development and analytical characterization, BioDlink applied strong technical expertise to define and lock robust process and analytical strategies, enabling successful scale-up and batch release. Through continuous process optimization, development, manufacturing, and regulatory submission activities were completed 1.5 months ahead of plan, exceeding client expectations and demonstrating strong execution capability, which earned high recognition from Kanghong Pharmaceutical for BioDlink's technical expertise and service excellence. Advancing Innovation in ADC Development The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink remains committed to providing end-to-end CDMO services to global partners, accelerating the development of complex biologics from early development through commercialization. About Kanghong PharmaceuticalKanghong is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, neuropsychiatric and others. Kanghong is devoted to the lives of patients through high quality, innovation and responsibility. Since its establishment, the company keeps researching, producing, and commercializing safer and more efficient drugs for pressing unmet medical needs. The company's purpose is to fundamentally improve patients' physical ability and social medical efficacy by using innovative science and breakthrough treatments to achieve progress in human health. About BioDlinkBioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs/XDCs). Headquartered in Suzhou with centers in Shanghai and Beijing, the company provides fully integrated, end-to-end services spanning early R&D through commercial manufacturing. With its one-base integrated platform and proprietary technologies—such as BDKcell® for rapid cell line development and GL-DisacLink® for site-specific conjugation—BioDlink helps partners accelerate development, improve efficiency, and reduce costs. The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across China, Indonesia, Nigeria, Pakistan, Colombia and Bolivian. Guided by the philosophy of "Quality First, Innovation Driven, Success Together", BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: https://biodlink.com/
2026-02-09 13:00:00

0.03093695640564


Nouvelles
Nouvelles

Dernières nouvelles et titres
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the wo...
Nouvelles